

WILEX AG



WKN: 661472 ISIN: DE0006614720 Land: Deutschland

Nachricht vom 06.07.2010 | 10:08

## WILEX AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

WILEX AG / Release of an announcement according to Article 27a Section 1 of the WpHG

06.07.2010 10:08

Dissemination of a Voting Rights announcement, transmitted by DGAP - a company of EquityStory AG.  
The issuer is solely responsible for the content of this announcement.

-----

Notification pursuant to section 27a para. 1 of the German Securities Trading Act (WpHG)  
Convenience Translation

UCB Pharma S.A., Brussels, Belgium, announced in a notice dated 9 June 2010 that its shareholdings had surpassed the threshold of 15% on 7 June 2010. Pursuant to section 22 para. 1 sentence 1 no. 1 and 5 German Securities Trading Act, the voting shares are attributable to the following companies:

1. UCB S.A., Brussels, Belgium
2. Financière de Tubize S.A., Brussels, Belgium

By notification dated 5 July 2010, both UCB Pharma S.A., UCB S.A. and Financière de Tubize S.A. (hereinafter 'Notifying Parties') informed the Company of the following in accordance with section 27a para. 1 German Securities Trading Act concerning the aims underlying the purchase of the voting rights and the origin of the funds used to purchase the voting rights:

I. The investment is aimed at implementing strategic objectives and not at generating a trading profit. Due to its specialisation in oncology, the issuer is the ideal strategic partner for the development of an oncologic product portfolio.

II. In general it is planned to participate in capital increases of the company within the next twelve months to secure the strategic objective pursuing the shareholding, if the economic and legal conditions are met. If it should be seen as necessary and/or useful for securing the strategic objective pursued with the shareholding, other arising possibilities to increase the amount of voting rights will also be considered in the future.

III. Ms. Professor Dr. Iris Löw-Friedrich, Chief Medical Officer and Executive Vice President Global Projects and Development, UCB S.A, is a member of the issuers' Supervisory Board. Also in the future it is desired to have an adequate - in relation to the size of shareholding - representation in the issuer's Supervisory Board. Also, the possibilities to exert influence, associated with the shareholding, on the appointment or removal of members of the issuer's administrative, management and supervisory bodies will be actively exercised.

IV. Presently, no essential change in the capital structure of the company, in particular with regard to the equity and debt ratio and dividend policy, is intended. If a respective question arises in the future and if it would be seen as necessary and/or useful for the strategic objective pursuing the shareholding, changes in the company's capital structure will be considered.

V. The funds used for purchasing the voting rights are 100% financed by own resources.

Munich, 6 July 2010

WILEX AG  
Executive Management Board

06.07.2010 Ad hoc announcement, Financial News and Media Release  
distributed by DGAP.  
Media archive at [www.dgap-medientreff.de](http://www.dgap-medientreff.de) and [www.dgap.de](http://www.dgap.de)

---

Language: English  
Company: WILEX AG  
Grillparzerstr. 10  
81675 München  
Deutschland  
Internet: [www.wilex.com](http://www.wilex.com)

End of News

DGAP News-Service

---